ASCO 2019 VIDEO: J. Leonard Lichtenfeld, MD
J. Leonard Lichtenfeld, MD, Acting Chief Medical and Scientific Officer, American Cancer...
Read More
ASCO 2019
Dr. Diefenbach and Dr. Dale
Catherine M. Diefenbach, MD, ASCO Spokesperson; NYU Langone Health William Dale, MD, PhD, ASCO...
Read More
ASCO 2019 VIDEO: Monica M. Bertagnolli, MD, Immediate Past-President, ASCO
Monica M. Bertagnolli, MD, Immediate Past-President, ASCO
Read More
ASCO 2019 Clinical Challenge: Are You an ASCO 2019 Expert?
The lights are out, the banners down, and the overflow rooms empty as the American Society of...
Read More
ASCO 2019: It Really Is All About the Targets
A quick run through the highlights and the headlines from the world’s biggest cancer meeting....
Read More
ASCO 2019: Investigational AKT Inhibitor Holds Promise in ER+ Disease
Potency is clear, but for capivasertib, toxicity is an issue CHICAGO – In a small study of...
Read More
ASCO 2019: Test All Triple Negative Breast Cancer Patients for PD-L1
Latest analysis from IMpassion trial confirms need for testing CHICAGO— One of the repeated themes...
Read More
ASCO 2019: Palbociclib Extends PFS in Young Women with HR+/HER2 Metastatic Breast Cancer
Korean study is first to show palbociclib benefit in premenopausal women CHICAGO—A second trial of...
Read More
ASCO 2019: NALA III Results Find ‘Modest Benefit’ for Neratinib Plus Capecitabine in Metastatic Breast Cancer
Findings hint at CNS benefit for neratinib By Peggy Peck, Editor-in-Chief, BreakingMED CHICAGO —A...
Read More
ASCO 2019: A Metavivor Offers Advice to Clinicians Treating Metastatic Breast Cancer
‘Don’t call my disease chronic.’ By Peggy Peck, Editor-in-Chief, BreakingMED CHICAGO — Kelli Davis...
Read More
ASCO 2019: SOPHIA Findings Pave Way for a New Tx Option in HER2+ Metastatic Breast Cancer
Benefit greatest in CD16A-158F carriers By Peggy Peck, Editor-in-Chief, BreakingMED CHICAGO...
Read More
ASCO 2019: CDK4/6 Inhibitors New Standard of Care for First-Line Tx
MONALEESA-7 results push the practice change needle By Peggy Peck, Editor-in-Chief, BreakingMED...
Read More
ASCO 2019: Researchers Hunt for Breast Cancer Resistance Genes
Pathways that get around PARP inhibitors explored CHICAGO – The cyclin-dependent kinase (CDK) 4/6...
Read More
ASCO 2019: Right to Try Act a Dud?
After a year, just 2 cases reported by FDA CHICAGO —At the one-year mark, the Right to Try Act,...
Read MoreASCO 2019: Adding Clinical Risk to Gene Scoring Predicts Likelihood of Breast Cancer Recurrence
More from TAILORx investigators By Peggy Peck, Editor-in-Chief, BreakingMED CHICAGO — Clinical risk — high versus low risk — integrated into a genomic risk model is prognostic of distant recurrence of breast cancer in women...
Read More
ASCO 2019: Olaparib Finds a Place to Treat Prostate Cancer
DNA repair mechanism damage targeted in advanced disease CHICAGO — Patients diagnosed with...
Read More
ASCO 2019: Men and Women Doctors Report Sexual Harassment
New survey highlights suspected financial impact CHICAGO – Gynecologic oncologists report that...
Read More
ASCO 2019: FDA Launches Project Facilitate to Ease Access to Novel Agents
But the FDA wants to know outcomes for patients taking unapproved drugs CHICAGO — The FDA says it...
Read More
ASCO 2019: New Agent Targets Metastatic Bladder Cancer
Metastatic disease responds to enfortumab vedotin CHICAGO – A new agent that acts as a smart bomb...
Read More
ASCO 2019: Laparoscopy for Liver Mets Equals Open Surgery
Colon cancer spread excised in minimally invasive procedure CHICAGO – In cases where colon cancer...
Read More- 1
- 2